Patients' preferences for adjuvant endocrine therapy in early breast cancer: What makes it worthwhile?

British Journal of Cancer

Volumn 93, Issue 12, 2005, Pages 1319-1323

  Duric, V M ^a   Fallowfield, L J ^b   Saunders, C ^c   Houghton, J ^d   Coates, A S ^e   Stockler, M R ^a,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Adjuvant endocrine therapy; Early breast cancer; Patient preferences

Indexed keywords

GOSERELIN; HORMONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FATIGUE; FEMALE; HOT FLUSH; HUMAN; INJECTION; INTERVIEW; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SWEATING; TABLET; WEIGHT GAIN;

EID: 28644436115     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602874     Document Type: Article

References (10)

1. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23: 1736-1750
2. Duric V, Stockler M (2001) Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2: 691-697
3. Duric VM, Stockier MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken NRC, Coates AS, Simes RJ (2005) Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC, CMF worthwhile now? Ann Oncol 16: 1786-1794
4. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
5. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
6. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 66: 73-81
7. Jansen SJ, Kievit J, Nooij MA, De Haes JC, Overpelt IM, van Slooten H, Maartense E, Stiggelbout AM (2001) Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 84: 1577-1585
8. Katz MH (1999) Multivariable analysis. A Practical Guide for Clinicians. Cambridge University Press
9. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30: 146-152
10. Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML (2005) What survival benefits do patients with premenopausal early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6: 581-588